216 related articles for article (PubMed ID: 37690631)
1. Comparative Effectiveness of Alternative Treatment Approaches to Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: An Observational Trial Emulation.
Platt A; Wilson J; Hall R; Ephraim PL; Morton S; Shafi T; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
Am J Kidney Dis; 2024 Jan; 83(1):58-70. PubMed ID: 37690631
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
4. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy.
Eandi M; Pradelli L; Iannazzo S; Chiroli S; Pontoriero G
Pharmacoeconomics; 2010; 28(11):1041-54. PubMed ID: 20936886
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism.
Ureña-Torres P; Bridges I; Christiano C; Cournoyer SH; Cooper K; Farouk M; Kopyt NP; Rodriguez M; Zehnder D; Covic A
Nephrol Dial Transplant; 2013 May; 28(5):1241-54. PubMed ID: 23328710
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
Xu J; Yang Y; Ma L; Fu P; Peng H
Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
[TBL] [Abstract][Full Text] [Related]
12. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
[TBL] [Abstract][Full Text] [Related]
13. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G
Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
[TBL] [Abstract][Full Text] [Related]
15. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study.
Ketteler M; Martin KJ; Wolf M; Amdahl M; Cozzolino M; Goldsmith D; Sharma A; Marx S; Khan S
Nephrol Dial Transplant; 2012 Aug; 27(8):3270-8. PubMed ID: 22387567
[TBL] [Abstract][Full Text] [Related]
16. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
17. Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study.
Ketteler M; Martin KJ; Cozzolino M; Goldsmith D; Sharma A; Khan S; Dumas E; Amdahl M; Marx S; Audhya P
Nephrol Dial Transplant; 2012 May; 27(5):1942-9. PubMed ID: 21931122
[TBL] [Abstract][Full Text] [Related]
18. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
19. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)].
Reichel H; Braun J
Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622
[TBL] [Abstract][Full Text] [Related]
20. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG
J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
